Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
City of Hope · Institut Gustave Roussy · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
191
total citations
- FWCI
- 46.22
- Percentile
- 100%
- References
- 38
Citations per year
Authors
23Topics & keywords
Topics
Keywords
- Cabozantinib
- Atezolizumab
- Medicine
- Renal cell carcinoma
- Oncology
- Internal medicine
- Immunotherapy
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- ELEli Lilly and CompanyAward: 5P30CA006516
- PPfizerAward: P30 CA008748
- AAstraZeneca
- GGlaxoSmithKline
- RRoche
- SSanofi
- GSGilead Sciences
- ASAmerican Society of Clinical OncologyAward: P30 CA008748
- FHF. Hoffmann-La RocheAward: P30 CA008748
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- DCDana-Farber/Harvard Cancer CenterAwards: 2P50CA101942-16, 5P30CA006516-56, 5P30CA006516
- EExelixisAward: P30 CA008748
- NCNational Comprehensive Cancer NetworkAward: CA008748
- COClovis Oncology
- IIncyte
- SSeagen
- EEisaiAward: P30 CA008748
- APAstellas Pharma
- ESEuropean Society for Medical Oncology
- IIpsen
- EPEUSA Pharma
- GGenentechAward: P30 CA008748
- ESEMD Serono
- BVBayer Vital
- NCNational Cancer InstituteAwards: 2P50CA101942-16, CA008748, P30 CA008748, 5P30CA006516, 5P30CA006516-56
- CCilag